[关键词]
[摘要]
目的：研究玻璃体腔注射康柏西普(Conbercept)治疗湿性老年性黄斑变性(wet age-related macular degeneration， wAMD)和息肉状脉络膜血管病变(polypoidal choroidal vasculopathy， PCV)的疗效。
方法：临床确诊为wAMD患者16例16眼，确诊为PCV患者5例5眼纳入研究。所有患者常规行玻璃体腔注射康柏西普治疗，根据需要补充治疗。定期行最佳矫正视力和中央视网膜厚度、脉络膜厚度测量。
结果：6mo时平均注射次数为2.93±0.27。基线及6mo时平均最佳矫正视力分别为0.87±0.52和0.74±0.43，差异无统计学意义。6mo时视网膜中央厚度从352.24±131.82降至251.73±69.41μm(P<0.01)，脉络膜厚度从331.93±115.35降至304.72±104.59μm(P<0.05)。
结论：玻璃体腔注射康柏西普治疗wAMD及PCV可稳定视力，降低患眼视网膜厚度，具有良好的安全性。
[Key word]
[Abstract]
AIM:To investigate the clinical effect of intravitreal conbercept on wet age-related macular degeneration(wAMD)and polypoidal choroidal vasculopathy(PCV).
METHODS: Sixteen patients(16 eyes)with wAMD and 5 patients(5 eyes)with PCV, both clinical diagnosed, were enrolled. All patients were treated with intravitreous conbercept.Additional treatments were administered if needed. Best corrected visual acuity(BCVA), central retinal thickness(CRT)and choroidal thickness(CT)were measured periodically.
RESULTS:The mean injection times at 6mo was 2.93±0.27. The mean BCVAs were 0.87±0.52 at baseline and 0.74±0.43 at 6mo, which the difference was not statistically significant. The mean CRT significantly improved from 352.24±131.82 to 251.73±69.41μm at 6mo(P<0.01). The mean CT reduced from 331.93±115.35 to 304.72±104.59μm(P<0.05).
CONCLUSION:Intravitreal conbercept can keep the visual acuity stable, reduce the retinal thickness and is safe on treating wAMD and PCV.
[中图分类号]
[基金项目]
